The FDA approved dupilumab to treat children aged 2 to 11 years with chronic spontaneous urticaria and persistent symptoms ...

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with CSU ...

Pediatric approval leveraged CupidKids pharmacokinetic bridging and safety assessments, with adverse events consistent across ...

Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin ...

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin ...

Dupixent, a chronic hives drug developed by Regeneron Pharmaceuticals and Sanofi, received approval from the Food and Drug Administration to treat children between the ages of two and 11 years old.

Sanofi wins FDA nod to expand Dupixent in kids aged 2-11 years, marking the first biologic for young patients with ...

The FDA has extended the approval of dupilumab to children aged 2-11 years with chronic spontaneous urticaria (CSU) who remain symptomatic despite treatment with histamine 1 antihistamines (H1AH), ...

The expanded approval was based on data extrapolated from Study A, B, and C of the LIBERTY-CUPID program and supportive pharmacokinetics data from the single-arm CUPIDKids study.

Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria Approval for children aged two to 11 years with ...

Sanofi ( SNY) and Regeneron’s ( REGN) Dupixent was approved in the U.S. as the first biologic medicine for young children ...

Hives aren’t just linked to insect bites. They can be triggered by food, medication, temperature changes, illness or stress.